Thursday 16 October, 2025
Introduction: Tapentadol is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake, making it effective for managing various types of…
Read morePoster: Drug/Disease Modelling - CNS
Evaluating a-priori fraction unbound predictions against brain homogenate data: Accounting for the experimental bias
Thursday 16 October, 2025
Objectives: Unbound brain exposure is a critical factor in central nervous system (CNS) drug development, which requires information on the…
Read moreIn Situ, In Vitro, and In Silico Permeability Values as Inputs for Blood-Brain Barrier Penetration Prediction: Impact on Brain Exposure for Passively Diffusing Compounds, with Ethanol as a Case Study
Thursday 16 October, 2025
Introduction: For compounds acting on the central nervous system (CNS), predicting brain concentrations is crucial, as it often differs significantly…
Read moreQuantification of subjective effects of esketamine and its metabolite esnorketamine in healthy volunteers using a bounded integer modeling approach
Thursday 16 October, 2025
Introduction Esketamine is a dissociative NMDA-receptor antagonist registered for the treatment of therapy resistant depression. Oral administration of esketamine would…
Read moreSemi-Mechanistic Pharmacokinetic Model of Intranasal Fingolimod hydrochloride Administration in Mice
Thursday 16 October, 2025
Introduction/Objectives: Fingolimod hydrochloride (FH) is a sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of multiple sclerosis (MS). Despite its…
Read moreTranslational mPBPK-PD modeling to investigate the determinants of human dose prediction for ASO candidates in CNS diseases
Thursday 16 October, 2025
Introduction/Objectives: Antisense oligonucleotide (ASO) is a promising therapeutic modality allowing to specifically modulate protein expression. Clinical development in brain disorders…
Read moreTranslational Physiologically Based Pharmacokinetic Modelling of Moxifloxacin for Optimizing Treatment of Tuberculous Meningitis
Thursday 16 October, 2025
Introduction: Tuberculous meningitis (TBM) is the most lethal form of tuberculosis, with mortality ranging between 20 – 70% [1]. For…
Read moreExposure-response analysis of minzasolmin in Parkinson’s disease using a lean fit for purpose approach to inform decision making
Thursday 16 October, 2025
Introduction: Minzasolmin is an orally available inhibitor of alpha-synuclein (ASYN) misfolding and subsequent aggregation. Aggregated forms of ASYN are the…
Read morePopulation pharmacokinetic-pharmacodynamic analysis of zolpidem to explore sex differences in healthy volunteers
Thursday 16 October, 2025
Objectives: Zolpidem is a non-benzodiazepine hypnotic agent used for the short-term treatment of insomnia, characterized by difficulty initiating sleep. According…
Read moreItem Response Theory Modeling of Digital-Motor Measures as the Primary Outcomes of Rare Degenerative Ataxias
Thursday 16 October, 2025
Background: Robust and sensitive outcomes are needed to enable precise estimation of disease severity, longitudinal changes, and treatment effects in…
Read more